Lifirafenib

Lifirafenib (BGB-283) is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively.

Product Specifications

CAS Number

[1446090-79-4]

Product Name Alternative

BGB-283

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

EGFR; Raf

Type

Reference compound

Related Pathways

JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/BGB-283.html

Purity

98.01

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C1NC2=NC=CC(OC3=CC=C(O[C@@]4([H])[C@]5([H])[C@@H]4C6=NC7=CC=C(C(F)(F)F)C=C7N6)C5=C3)=C2CC1

Molecular Formula

C25H17F3N4O3

Molecular Weight

478.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Tang Z, et al. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14 (10) :2187-97.